EC-18 has been shown pre-clinically to control the inflammatory cytokine and chemokine signaling that has been implicated in these severe COVID-19 cases. EC-18 has also been shown to improve lung function, as well as to reduce inflammation and fibrosis, in multiple animal models of immune-mediated acute lung injury and also other inflammatory diseases, such as pneumonia.

EC-18 is currently in Phase 2 clinical trials in South Korea and the U.S. 

Dr. Cameron Robert Wolfe, an associate professor of medicine at Duke University School of Medicine, and an internationally renowned specialist in infectious diseases, is the lead scientific advisor to Enzychem’s COVID-19 program in the US.